ASCENTAGE PHARMA GR-ADR (AAPG) Stock News

USA - NASDAQ:AAPG - ADR

39.78 USD

+0.2 (+0.51%)

Last: 10/2/2025, 3:37:05 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AAPG Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Zacks Investment Research

Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock?

a month ago - By: Zacks Investment Research

Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now

a month ago - By: Benzinga - Mentions: AXGN AMBR GCT IOVA ...

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

a month ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025

a month ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

a month ago - By: Benzinga - Mentions: KC COTY CAAP BIDU ...

Earnings Scheduled For August 20, 2025

2 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

2 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

2 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma to Participate in Evercore China Biotech Summit

3 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

3 months ago - By: Yahoo Finance

Ascentage Pharma’s Novel Cancer Drug Approved in China

3 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Pricing of Top-Up Placement

3 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Proposed Top-Up Placement

3 months ago - By: Yahoo Finance - Mentions: UBS ACHC

UBS Reiterates a Buy Rating on Acadia Healthcare (ACHC) With a $45 Price Target

3 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

3 months ago - By: Yahoo Finance - Mentions: NVS VZ 6855 NOVN

Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance

3 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

3 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

4 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

5 months ago - By: Yahoo Finance

Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?

5 months ago - By: Yahoo Finance - Mentions: VZ ALHC BRKR MAGN ...

3 Ways Your Kids Can Start Saving for Retirement Now

5 months ago - By: Yahoo Finance - Mentions: LLY NVO DHI CMG

President Trump Just Announced Terrible News for Eli Lilly Investors

5 months ago - By: Yahoo Finance - Mentions: VZ IONS AMZN KO ...

Trump’s Tariffs: 7 Things To Do Now If You’re Worried About the Unpredictable Stock Markets

5 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

5 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

5 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

5 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

5 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

5 months ago - By: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines